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ABSTRACT 
Objective: Antipsychotic drug efficacy may have decreased over the decades. We, therefore, present a 
comprehensive meta-analysis of all placebo-controlled trials in acute schizophrenia, we investigate which 
trial characteristics have changed over the years and which ones are moderators of drug-placebo efficacy 
differences. 
Method: We searched multiple electronic databases, ClinicalTrials.gov and the FDA website. The 
outcomes were overall efficacy (primary outcome), responder rates, drop-out rates, positive, negative and 
depressive symptoms, quality of life, functioning, and major side-effects. Multiple potential moderators of 
overall efficacy were analyzed by meta-regression.  
Results: 167 double-blind randomized controlled trials with 28102 participants were included. The 
standardized mean difference (SMD) for overall efficacy was 0.47 (95% CrI 0.42,0.51), but accounting for 
small trial effects/publication bias reduced the SMD to 0.38. 51% in the antipsychotic group versus 30% 
in placebo had at least a ‘minimal’ response, and 23% versus 14% had a ‘good’ response. Positive 
symptoms improved more than negative symptoms and depression. There were also small-to medium 
sized improvements in quality of life and functioning (SMDs 0.35 and 0.34). In the analysis of response 
predictors, 17 of 26 trial characteristics analyzed changed over the decades. But in a multivariable meta-
regression, only industry-sponsorship and increasing placebo response were significant moderators of 
effect sizes. Importantly, drug response remained stable over time.  
Conclusions: Approximately two times more patients improved under antipsychotics compared to 
placebo, but only a minority experienced a good response. Industry sponsorship reduced, rather than 
increased effect sizes. The decrease of effect sizes over the years was caused by increasing placebo 
response, not by decreasing drug response. Meta-analyses need to take this confounder into account. In 
drug development, somewhat smaller sample sizes but better selected patients may overcome a possible 
vicious circle of increasing sample sizes, more variability and smaller effect sizes.  
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INTRODUCTION 
Antipsychotics are attacked by distinguished physicians such as prestigious researchers of the Cochrane 
Collaboration (1) and others (2). This criticism makes the lay public (3), patients (4), general physicians 
and policy makers skeptical. The skepticism is driven by the fact that most placebo-controlled studies are 
conducted by the pharmaceutical industry which is not trusted (5, 6), an issue that we examine here. The 
essence of the criticism is that antipsychotic drugs have multiple side-effects, but only little efficacy, and 
that therefore their use should be restricted to a minimum (1). 
 Indeed, an early, large (487 participants) NIMH-sponsored trial from 1964 which is often used as 
a reference for antipsychotic drug efficacy showed a substantial difference between antipsychotics and 
placebo (61% versus 22% were much improved). In contrast, in recent years, there have been a number of 
failed trials where even standard drugs such as haloperidol did not outperform placebo (7). A systematic 
review and meta-regression suggested that increasing placebo response could explain this phenomenon. 
However it only analyzed predictors of placebo response, but it had little on the improvement on drug 
above placebo, which is crucial for patients (8). Drug-response could well have increased in parallel to 
placebo-response, so that the net effect would be the same. Therefore, there is a need to identify predictors 
of drug-placebo differences beyond the predictors of placebo-response identified in this previous review 
(8). Another analysis suggested a parallel decrease in drug response, but it included only a small number 
of placebo-controlled trials, so that drug response was dominated by active controlled trials which are very 
different from placebo-controlled trials. It is not plausible that drug-response decreases when placebo-
response increases making a re-assessment important (see discussion) (9). Finally, a recent network meta-
analysis did not provide a meta-regression of efficacy predictors. Moreover, it primarily examined newer 
second-generation antipsychotics (and only two of 52 old ones; http://www.whocc.no/), thus offered 
limited information on the first forty years of antipsychotic drugs (10).  
 In this context, we present a comprehensive systematic review of all acute phase, placebo-
controlled antipsychotic drug trials in schizophrenia since the introduction of chlorpromazine in 1953, 
addressing efficacy, tolerability, and quality of life and functioning on which information is increasingly 
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asked for. We explored with meta-regression which trial characteristics have changed over the years and 
which ones are moderators of drug-placebo differences. The results of this broad summary of the first 60 
years of antipsychotic trials should inform clinicians, should provide clues for the future design of 
antipsychotic drugs trials and should help to put the debate about antipsychotic drugs on a rational basis. 
 
METHODS 
We followed the PRISMA guidelines (11) (checklist in Table S1 of the data supplement) and initially 
published a protocol in PROSPERO (CRD42013003342, data supplement Table S2). 
 
Inclusion/exclusion criteria 
Participants 
Adults with acute exacerbations of schizophrenia or related disorders (following the Cochrane 
Schizophrenia Group we accepted all diagnostic criteria and we also included schizoaffective, 
schizophreniform, or delusional disorder, because these do not require generally different treatment (12)). 
We excluded relapse prevention studies in stable patients receiving maintenance medication (13), in 
patients with predominant negative symptoms, and in patients with major concomitant somatic or 
psychiatric illness.  
Interventions 
We included all antipsychotics licensed in at least one country, except clozapine, a more efficacious drug 
(10), so that pooling with the other compounds would not have been appropriate (only one clozapine arm 
with nine patients had to be excluded on this basis(14) making the impact of this decision negligible). We 
excluded intramuscular formulations, because these are used primarily as sources either for emergency use 
(short-acting i.m. drugs) or for relapse prevention (long-acting depot drugs). Both flexible- and  -fixed- 
dose studies were included. All flexible-dose studies were included because they allow investigators to 
titrate to an adequate dose. Of fixed-dose studies we only included target- to- maximum doses according 
to the International-Consensus-Study-of-Antipsychotic-Dosing (15). We averaged the results of eligible 
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fixed doses of single studies with appropriate formulas before entering the study in the meta-analysis 
(Cochrane Handbook (16)). 
Types of studies 
Published and unpublished, double-blind, placebo-controlled randomized controlled trials of at least 3 
weeks duration (17). Studies with a high risk in sequence generation or allocation concealment were 
excluded (16). We a priori excluded Chinese studies due to serious quality concerns (18, 19). Risk of bias 
was independently assessed by at least two of the following reviewers (CL, SL, MH, BH) with the 
Cochrane Collaboration’s risk-of-bias-tool (16).  
 
Search strategy 
We searched the Cochrane-Schizophrenia-Group-Controlled-Trials-Register (compiled by regular 
systematic searches of more than 15 databases, clinical trial registers, the FDA website, hand searches and 
conference proceedings (20), without language restrictions, available to us until version August 2009) 
with the term “placebo”; and we searched MEDLINE, EMBASE, PsychInfo, Cochrane CENTRAL and 
ClinicalTrials.gov (last search October 2016, online Table S3 presents search terms), supplemented by 
screening previous reviews (8, 10, 21-29).  
 
Outcomes 
1. The primary outcome was the mean overall change in symptoms, with the following order: change in 
Positive and Negative Syndrome Scale (PANSS, (30)) total score; if not available, change in Brief 
Psychiatric Rating Scale (BPRS, (31)); then endpoint values of these scales; then other published 
schizophrenia rating scales (32).  
2. Responders: We analyzed how many patients achieved a) at least a “minimal response”, defined as 
either at least 20% PANSS/BPRS reduction from baseline or a CGI at least slightly improved (33-35); and 
b) a “good  response” – either at least 50% PANSS/BPRS reduction or CGI at least much improved (33-
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35). Results of the single definitions were consistent and were presented separately, as well. We also 
analyzed c) any study-defined definition. 
3. Discontinuation: Drop-outs due to a) any cause, b) inefficacy. 
4. Positive, negative and depressive symptoms, quality of life, social functioning (measured by published 
rating scales (32)) 
6. Major side-effects: extrapyramidal side-effects (antiparkinson medication use at least once), weight 
gain, sedation, prolactin increase and QTc prolongation. 
 
Study selection and data extraction 
At least two reviewers among MH, MT, MS and SL independently selected potentially relevant 
publications from the abstracts found by our search and decided to include studies, and at least two 
reviewers among CL, MH, BH, MS, MR, SB, MK, PR, TA, NP and SL (see acknowledgement) extracted 
data in duplicate in Excel sheets. Disagreement was resolved by discussion. Missing data were requested 
from authors or the sponsoring pharmaceutical companies for all studies published in the last 30 years. We 
preferably extracted intention-to-treat data and we preferred mixed-effect-model-of-repeated-
measurements (MMRM) models over last-observation-carried-forward (LOCF). For dichotomous data we 
assumed that participants lost to follow-up would not have responded (conservative approach). Missing 
standard deviations were estimated from test statistics or by using the mean standard deviation of the 
remaining studies (36, 37).  
 
Statistical synthesis of study results 
We used a Bayesian hierarchical random-effects model in OpenBUGS 3.2.3 to estimate summary effect 
sizes for each outcome as heterogeneity was expected. We primarily examined all antipsychotics as a 
group because efficacy differences between drugs are small (10, 38-40), but results of individual drugs are 
presented as well. For the primary analysis we merged the different antipsychotic arms within multi-arm 
trials (16) but properly accounted for the inherent correlation in the drug-specific analyses. We estimated 
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standardized mean differences for continuous outcomes and risk ratios for dichotomous outcomes, 
together with their 95% credible intervals (CrI). Numbers-needed-to-treat-to-benefit/harm were estimated 
using the meta-analytic summary of an outcome in all placebo arms. Heterogeneity was assessed by visual 
inspection, the between study standard deviation and the I-square statistic (values > 50% were considered 
as considerable heterogeneity (41)). 
 
Meta-regression analyses 
We meta-regressed publication year and the frequency of the moderators to explore which trial 
characteristics have changed over time.* Then, in meta-regressions of the primary outcome we were 
particularly interested in exploring whether the drug-placebo difference became smaller over the decades 
and we systematically examined all possible moderators, reported by previous evidence (8, 9, 42-44), that 
might explain this phenomenon. We categorized the moderators into patient-, drug-, and study design 
related factors, although there were expected overlaps. Moderators that were significant in univariable 
analyses were included in a multivariable meta-regression model. To identify the most important 
moderators from this model we used the stochastic search variable selection algorithm to estimate the 
probability that each variable should be included in the meta-regression model (see protocol, Table S2 
(45)). To measure the strength of a moderator we compared the meta-regression models with the meta-
analysis without covariates and estimated the percentage of heterogeneity explained by a moderator. 
Meta-regressions were not performed on individual drugs, because statistical power would have been 
insufficient for most of them. Post-hoc analyses following recent research (e.g. Agid et al.(8)) are marked 
with an asterix*.  
Patient related factors 
The patient-related factors were: chronicity (8) measured by the patients’ age, duration of illness, duration 
of the current episode and first episode status (8, 43);percentage men (43); US American populations 
versus not/mixed countries (46); degree of placebo response (8) and degree of drug (9) response* (both 
measured by the PANSS change or the BPRS change converted to the PANSS using a validated method 
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(47)); severity at baseline (PANSS total score (48)), in- versus outpatient (8); and operationalized criteria 
(e.g. ICD-10 or DSM-III to IV-R) versus unspecific ‘clinical diagnoses’.  
Drug related factors 
We classified the antipsychotics by their mechanisms according to the “Neuroscience-based 
Nomenclature” (49); antipsychotic doses in chlorpromazine equivalents according to the International-
Consensus-Study-of Antipsychotic-Dosing (9, 15); and fixed versus flexible dose studies (44).  
Study design related factors 
We analyzed the impact of risk of bias (appropriate versus unclear randomization (50) and allocation 
concealment methods (51),blinding (51), and missing outcome data (16, 52)); study duration (8); duration 
of wash-out (8); requirement of a scale-derived minimum of symptoms at baseline (48); PANSS versus 
BPRS as a scale; sample size (53); number of sites (8); percentage of academic sites (8)*; number of 
medications and arms (8);percentage of participants randomized to placebo (44); and drug company 
sponsorship of at least one study arm (medication donation alone was not considered company 
sponsorship (6)).  
 
Sensitivity analyses of the primary outcome 
We applied a fixed-effects instead of a random-effects model, we calculated odds ratios and we excluded 
studies based on study completers. We explored whether the effect sizes of haloperidol, the only drug for 
which both early and recent studies were available, had decreased over the years, as well.*   
 
Publication bias 
We used contour enhanced funnel-plots (54), a selection model (software OPEN BUGS (55)), and the 
trim-and-fill method (56) to assess whether eventual small trial effects were likely due to publication bias 
(Table S2 presents details).  
 
 
 10 
RESULTS 
Description of included studies  
Supplemental Figure S1 presents the PRISMA (11) flow diagram. Overall, 167 studies published from 
1955 to 2016 with 28102 participants were included (see Table S4). The mean duration of illness was 13.4 
(SD 4.7) years, the mean age 38.7 (SD 5.5) years and the median duration of studies with useable 
outcomes was 6 weeks (range 3-28 weeks, for the primary outcome all but one study lasted ≤12 weeks, 
one study without any useable outcomes lasted 156 weeks). There were no studies exclusively examining 
first-episode patients or treatment resistant patients. In studies on acutely ill patients, the most frequently 
used drugs with data for at least one outcome were chlorpromazine (36 studies), haloperidol (28 studies), 
olanzapine (20 studies), risperidone (15 studies), quetiapine (8 studies), paliperidone (8 studies), 
aripiprazole (9 studies), thioridazine (7 studies), lurasidone (7 studies), asenapine (6 studies) and loxapine 
(6 studies), for all other drugs less than 5 studies were available. Risk of bias is presented in supplemental 
Table S6. We only included randomised, double-blind trials, but the reports often did not indicate full 
details about sequence generation, allocation concealment, although this has improved over the years (see 
Table 1). Descriptions of methods and success of blinding were frequently insufficient, as well. The data 
confirmed the high dropout rates in current schizophrenia studies (mean 37.2%, SD 20.5). Older studies 
were poorly reported, making it often impossible to extract outcome data (50% of the studies had a high 
risk of selective reporting). Finally, 70 studies (42%) were sponsored by the manufacturers of one 
antipsychotic included, 72 (43%) were not primarily industry sponsored and in 25 (15%) studies the 
sponsor was unclear. 
 
Outcome results 
The mean effect size of all studies combined was 0.47 (95% CrI 0.42,0.51; I2 52%; 105 studies (N) with 
22741 participants (n)). Patients treated with antipsychotics were twice as likely to respond as those on 
placebo when any response criterion was accepted [N=97, n=20690, response ratio 1.93 (1.72,2.19), 
number-needed-to-treat-to-benefit 6 (5,8), I2 61%]. 51% of the antipsychotic-treated patients compared to 
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30% on placebo had at least a ‘minimal’ response [N=46, n=8918, response ratio 1.75 (1.59,1.97), 
number-needed-to-treat-to-benefit 5 (4,5)], while 23% versus 14% had a ‘good’ response [N=38, n=8403, 
response ratio 1.96 (1.65,2.44), number-needed-to-treat-to-benefit 8 (6,11)]; Figure 1. Similar results were 
obtained when responder rates based on PANSS/BPRS or CGI were analyzed separately (Table S6, which 
also presents odd ratios).  
 Participants on placebo were more likely to discontinue the studies prematurely, both for any 
reason [38% drug, 56% placebo, N=105, n=22851, risk ratio 1.25 (1.20,1.31), number-needed-to-treat-to-
benefit 11 (9,14), I2 19%] and for inefficacy of treatment [13% drug, 26% placebo, N=94, n=23017, risk 
ratio 2.09 (1.90,2.32), number-needed-to-treat-to-benefit 7 (6,9), I2 46%].  
 The effect size for positive symptoms [N=64, n=18174, SMD 0.45 (0.40,0.50), I2 56%] was 
similar to that of overall symptoms, while effects on negative symptoms [N=69, n=18632, SMD 0.35 
(0.31,0.40), I2 42%], and depression [N=33, n=9658, SMD=0.27 (0.20,0.34), I2 50%] were smaller.  
 Based on six trials the quality of life of participants in the antipsychotic groups was better than 
that in the placebo group [N=6, n=1900, SMD 0.35 (0.16,0.51), I2 43%], and so were improvements in 
social functioning in ten trials [N=10, n=3077, SMD 0.34 (0.21,0.47), I2 46%] (Figure 2).  
 Antipsychotic drugs produced more movement disorders [antiparkinson medication use 19% drug, 
10% placebo, N=63, n=14942, risk ratio 1.93 (1.65, 2.29), number-needed-to-treat-to-harm 12 (9,16), I2 
51%], were more sedating [14% sedated versus 6%, N=86, n=18574, risk ratio 2.80 (2.30,3.55), I2 54%], 
led to more weight gain [N=59, n=17076, SMD -0.40 (-0.47,-0.33), I2 73%], to more prolactin increase 
[N=51, n=15219, SMD -0.43 (-0.55,-0.30), I2 91%], and to more QTc prolongation [N=29, n=9883, SMD 
-0.19 (-0.29,-0.08), I2 80%] than placebo. Individual drugs are presented in Figures 3 and 4 and in suppl. 
Figure S2.  
 
Change of trial characteristics over time  
Table 1 shows that several trial characteristics changed significantly over the years: the number of 
participants and sites, the use of minimum baseline severity as inclusion criteria, fixed-dose designs, use 
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of operationalized criteria, use of the PANSS, percentage of men, studies outside the US and placebo-
response increased, while the duration of the wash-out periods, use of dopamine D2 antagonists (49), 
study duration, risk of bias in terms of incomplete outcome data, mean doses and the number of academic 
sites decreased. 
 
Moderators of the efficacy of antipsychotics – univariable analysis 
Effect sizes have become smaller over the years. The coefficient of -0.08 in Table 2 indicates that a study 
published 10 years later than another one had, on average, a 0.08 units lower effect size. Figure 5 
demonstrates this effect not only for all antipsychotics as a class (Figure 5a), but also for haloperidol, the 
only antipsychotic for which both early and recent studies were available (Figure 5b). Moreover, Figures 
5c and 5d show that the decrease of effect size was paralleled by an increase in placebo response while 
drug response remained quite stable which contradicts a previous analysis (9).  
 Significant study design related factors were: larger sample size (total number of participants and 
sites), number of drugs, PANSS rather than BPRS, a minimum of symptoms as an entry criterion, and 
industry sponsorship. With the exception of ‘number of drugs’ all these factors were associated with 
smaller effect sizes (Table 2).  
 Significant patient or drug- related factors were: operationalised rather than clinical diagnostic 
criteria, higher placebo response rates, lower dose, and D2, 5-HT1A receptor partial agonists vs D2 
antagonists (mainly haloperidol), all of which were associated with smaller effect sizes (Table 2).  
 
Moderators of the efficacy of antipsychotics – multivariable analysis 
As several significant predictors are related by nature, we made the following choices for the 
multivariable model: a) We chose sample size as representative for the number of sites, number of drugs 
and number of arms. b) We chose publication year to represent the use of operationalized criteria (such 
criteria did not exist for early studies) and of PANSS (introduced in 1987) versus BPRS, and of drug 
mechanisms according to NbN (49)) which also changed over the years.  Only pharmaceutical sponsorship 
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and the degree of placebo response remained significant and resulted in large probabilities from the 
variable selection algorithm (82.8% and 81.6% respectively) implying that they are probably the most 
important moderators. Studies with a 10 PANSS points larger placebo response, on average, had a 0.13 
smaller effect size, and, surprisingly, industry sponsored studies, on average, had a 0.16 smaller effect size 
compared to non-industry sponsored trials (Table 3).  
Both predictors remained the only significant ones in a post-hoc sensitivity analysis where all significant 
moderators were entered. When pharmaceutical sponsorship – which is probably a composite of various 
factors – was removed from the model in another sensitivity analysis, only degree of placebo response 
remained significant, demonstrating the strength of this factor. Both sensitivity analyses had less 
explanatory power than the primary analysis, however (31.3% heterogeneity explained in the primary 
model versus 18.8% in both sensitivity analyses, Table S7) 
 
Publication bias 
Contour enhanced funnel plots revealed small trial effects. As studies were missing in the area of non-
significant effect sizes (Figure 6) and as the selection model showed a strong correlation between 
probability of publication and magnitude of effect in various scenarios (range of correlation coefficients R 
= 0.66-0.85), part of the small trial effects is likely a result of publication bias. The publication bias 
‘adjusted’ SMD ranged between 0.36-0.41 in various scenarios of the selection model, corroborated by the 
trim-and-fill method [adjusted SMD 0.38 (0.33,0.43), Table S2].  
 
Sensitivity analyses 
The use of a fixed-effects rather than a random-effects model [N=105, n=22741, SMD=0.44 (0.42,0.47)] 
and the exclusion of completer analyses [N=95, n=22352, SMD= 0.46 (0.42,0.51)] did not significantly 
change the primary outcome, nor did the use of odds ratios (Table S6). 
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DISCUSSION 
This first comprehensive meta-analysis of all acute phase, placebo-controlled antipsychotic drug trials 
since the introduction of chlorpromazine presents multiple new analyses and results which can be 
important for clinical practice and trial methodology.  
Overall efficacy 
We examined two response criteria - ‘any’ response and a ‘good’ response to antipsychotics. This was 
important because previous systematic reviews (22-28) had analyzed whatever response criterion was 
presented in the individual studies, leading to a difficult-to-interpret criteria mix. Several analyses showed 
that 20% PANSS/BPRS reduction roughly corresponded to minimal improvement on the CGI and 50% 
PANSS/BPRS reduction to much improvement, and justified analysing them together (34, 57-59) (results 
of individual scales were similar, Table S6). Antipsychotic drugs clearly increased the number of patients 
with ‘any response’ (51% vs 30%), but, importantly, few patients (23% vs 14%) reached a ‘good’ 
response within the confines of short-term, double-blind trials. The mean effect size for overall symptoms 
(0.47) was only medium according to Cohen (60) and it translates to a 9.6 PANSS points difference. This 
contrasts with the large (n=463), early NIMH study from 1964 which has been used frequently as a 
benchmark for antipsychotic drug efficacy (61). Its impressive difference in response rates (61% under 
drug vs 22% under placebo showed much improvement) can be explained by the fact that approximately 
50% of patients suffered from their first episode or were antipsychotic naive (61). In the current review 
not a single study was restricted to first-episode patients. Thus, its results are only representative for 
chronic patients who respond less well to antipsychotics (62). In the future first-episode trials could 
provide better signal detection. Moreover the trials in a meta-analysis are weighted by their sample size. 
Thus, the mean effect size of 0.47 largely represents the effects of the avalanche of trials after the 
reintroduction of clozapine in 1990. In this context we caution that the efficacy effect sizes of the single 
drugs in Figure 3 and Figure S2 have not been adjusted for publication year. 
Negative symptoms and depression 
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 The current gold-standard for effects of antipsychotics on general negative symptoms is a meta-
analysis which erroneously found an almost two times higher superiority compared to placebo (SMD 0.58 
vs 0.35 here), but mistakenly standard errors rather than standard deviations were often used in the 
calculation of effect sizes which artificially inflated them (64). In our analysis antipsychotics the effect 
size for negative symptoms was smaller, but in a similar range than that for positive symptoms. However, 
as studies with primary negative symptoms were excluded, the effect-size might mainly reflect reductions 
of secondary negative symptoms (63). Similarly, the small effect of antipsychotics on depressive 
symptoms might also be a consequence of the reduction of positive symptoms and associated 
psychological distress. Nevertheless, some second-generation antipsychotics have proven efficacy in 
major depressive disorder (65).  
Side-effects 
 The only purpose of our side-effect analysis was to present a brief efficacy-tolerability trade-off in 
this class review. Effect sizes across drugs were medium with sometimes very large heterogeneity. This 
heterogeneity reflects the enormous differences of single antipsychotics in their side effects, and it 
suggests that careful choices can minimize the side-effect burden for individual patients. But we caution 
that sometimes small participant numbers which make results unreliable (reflected by large 95% credible 
intervals) must be considered in interpreting Figure 4 and supplemental Figure S2. 
Outcomes related to social integration 
 The results suggested a small to medium benefit of antipsychotics in quality of life. As in our 
systematic review on maintenance treatment with antipsychotics compared to placebo (13), only a few 
(six) recent trials reported on this crucial outcome which combines efficacy and safety and which might be 
more relevant for patients that the mere reduction of hallucinations and delusions, but with a sample size 
of 1900 patients the results are robust (66).  The same holds true for social functioning. More time 
may be needed until antipsychotics develop their full effects, but patients may want to know whether after 
approximately 6 weeks they are already doing better in this regard. Outcomes that help to understand  
whether antipsychotics also help social re-integration should become a standard (Figure 2). 
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Meta-regression of response predictors including industry sponsorship  
Table 1 shows that several study characteristics changed over the decades, and some of them were also 
significant predictors of drug-placebo differences:  
 In univariable analyses drug-placebo differences decreased over time with an average rate of 0.08 
effect size units per decade signifying that a study from 1970 would have an effect size of approximately 
0.74 and a study from 2015 of 0.38, a trend which has not been stopped by the most recent antipsychotics 
brexpiprazole and cariprazine which had relatively small effect sizes (Figure 3 and Figure S2). Publication 
year can only be a surrogate for other factors, but it is not surprising that trials without standardized 
diagnostic criteria or using the BPRS had larger effect sizes than trials with such criteria or using the 
PANSS, nor, that the old D2 antagonists had larger effect sizes than the recent D2/5-HT1a partial agonists. 
In the early studies standardized criteria and the PANSS were simply not available, and D2 antagonists 
were primarily examined in the older, smaller, trials. When we analyzed haloperidol separately, its 
superiority compared to placebo had become smaller over the years, as well, demonstrating that 
decreasing effect sizes over time cannot be explained solely by more recent drugs being less efficacious 
(Figure 5b). 
 Larger sample sizes and the related moderator, number of sites, were associated with smaller 
effect sizes, which is consistent with the funnel-plot suggesting substantial small-trial effects that are well-
known from other medical fields (53, 67). The patients of small trials might be better selected than those 
of large trials. In contrast, methodology of the often older, small trials was less stringent. For example, 
independent monitoring is a relative recent requirement. However, our specific tests suggest that studies 
were missing, at least in part, due to publication bias.  
 The purpose of minimum baseline severity thresholds is to have drug-responsive populations (48), 
but, counterintuitively, they had lower effect sizes, possibly because such criteria invited artificial baseline 
inflation. Although the direction of the effect changed in the multivariable analysis suggesting that this 
moderator might be confounded by another one, alternative ways to have severely ill populations should 
be considered. 
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 However, in the multivariable meta-regression, the only moderators that remained significant 
were the degree of placebo response, and industry sponsorship which, against criticisms and our 
expectations (6), was associated with smaller effect sizes. Industry studies are often large and involve 
multiple countries and sites, leading to problems such as cultural differences in the interpretation of 
psychopathology which may increase variability and decrease effect sizes. The “patent clock” is running 
down, thus patients are recruited quickly by professional centers. As multiple effective antipsychotics are 
available, patients think twice before consenting to a placebo-controlled trial and those who do consent 
can be a negative selection, such as (partial) non-responders to previous drugs or so-called “professional 
patients” who benefit from a free trial of medication answering a newspaper advertisement. These factors 
may also contribute to high placebo response. 
Differences to previous analyses  
Agid and colleagues (8) focused on predictors of placebo response while our research question was the 
drug-placebo difference. To explain placebo-response was important from a methodological point of 
view, but for patients and psychiatrists it is the drug-placebo difference that counts. In this context it was 
by no means self-explanatory that – together with pharmaceutical sponsorship -  placebo-response was the 
strongest predictor of efficacy effect sizes in our analysis. Some other factor could have well been more 
important, and a parallel increase of drug-response, which would have attenuated placebo-response, was a 
priori likely. Only a few significant predictors of placebo-response in Agid et al. (8) were also significant 
predictors of drug-placebo differences here, at least in univariable analyses (publication year and the 
number of sites). Another explanation than the different research question is that our database was two-
times larger which made our results more robust (50 randomized controlled trials in Agid et al.(8) versus 
105 here).  
 Rutherford and colleagues (9) addressed drug-placebo differences, but four out of six of the 
findings that they emphasized in their abstract were not confirmed by our multivariable analysis. They 
used multi-level meta-analysis and hierarchical modeling which is another valid method.  
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This difference in methods makes it unclear why Rutherford et al.’s (9) abstract findings trial duration and 
baseline severity were not significant in our analysis, but we had 2.5 times more placebo-controlled 
studies available which can have changed many findings. The major difference in results was that in 
Rutherford et al.’ analysis (9) increasing response in the placebo arms was paralleled by decreasing 
response in the drug arms. In our analysis drug response remained stable over the years (Figure 5d). In 
Rutherford et al. (9) many of the data on drug response (208 arms) were from trials that compared drugs 
head-to-head, not from placebo-controlled trials (39 arms (68)). Although trial type was statistically 
controlled for, this is a quite different population of trials. For example, dropout rates are much higher in 
placebo-controlled trials than in active-controlled trials (69). When we re-analyzed the drug-arms of 
Rutherford et al.’s 39 placebo controlled studies, drug response remained stable, as well (supplemental 
Table S8). Thus, drug response has only decreased in active controlled studies, not in placebo controlled 
studies. This has major implications for drug development: To improve signal detection in placebo 
controlled trials researchers needs to focus on reducing placebo response rather than on increasing drug 
response. Finally, Agid et al.(8) did not detect the publication bias and Rutherford et al. (9) didn’t explore 
it.  
Limitations 
The major limitation is that all antipsychotics were analyzed as a class, because efficacy differences 
between individual drugs are thought to be small (except clozapine, of which one trial with only 9 patients 
was excluded) (10, 70). The number of drugs involved rendered it impossible to fully control for the 
resulting heterogeneity. Additionally, many older studies were so poorly reported that it was impossible to 
extract outcome data. For example, two early,large Veterans Affairs studies (312 and 692 patients, 
respectively) showed a significant superiority of antipsychotics compared to placebo, however an effect 
size could not be calculated (71, 72). Only 46/38 studies reported on the number of participants with at 
least “minimal response” and “good response”. It is quite possible that some authors presented response 
data based on the cutoff showing the best result. Finally, conventional meta-analyses cannot detect subtle 
moderators of treatment effects. The main reason is ecological fallacy, i.e. that conclusions about 
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individuals which are based on analyses of group data can be biased. Another one is limited variability in 
the observed means which could be overcome by individual patient data meta-analyses which capture 
large inter-individual variability.  
 
Conclusions 
Our results are important on several levels.  
 First, clinicians can expect that approximately two times more patients improve under 
antipsychotics compared to placebo, but only a minority will experience a good response in the short-
term.We need to document better whether antipsychotics only suppress positive symptoms or whether 
they also help social re-integration reflected by improvements in social functioning and quality of life.  
 Second, network meta-analyses need to consider possible temporal changes. If placebo-controlled 
trials on one drug developed in the 1970s are combined with those of one developed in the 2010s, the 
older drug might artificially turn out better due to higher effect sizes in that period. In a previous report 
we, therefore, excluded placebo-controlled trials in a sensitivity analysis and examined publication year as 
a moderator (10).  
 Third, industry-sponsorship has not inflated effect sizes. But there was publication bias, because 
companies do not always publish inconclusive studies. Increasing placebo response, but not decreasing 
drug response, contributed to the decreasing effect sizes over time. Finally, sample size and related 
measures arose several times as significant, modifiable design features for drug development. There could 
be a vicious circle. Sample sizes have increased continually over the years (see Figure S3). Companies 
conduct large trials to assure statistical significance. The inclusion of many patients and sites leads to 
more recruitment pressure and variability which, by definition, reduces effect sizes (SMD=mean 
difference/standard deviation). The next sample size estimation will suggest an even larger sample. We 
recommend somewhat smaller studies, but, better selected patients to reverse this trend. 
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Table 1: Meta-regressions showing which trial characteristics have changed over the years 
Explanatory 
variablea Categories
 Weighted mean 
publication year 
Numb
er of 
studies 
Meta-
regression 
coefficient  
95% 
credible 
interval 
Study design 
related factors      
Number of total 
participantsa - - 105 79.77
b 58.50,101.03 
Number of sitesa   96 12.22b   9.57,14.91 
Academic sites (%)a - - 59 -13.75b   -19.75,-7.74 
Baseline severity 
entry minimum 
scorea 
No (ref) 1988 29 -  
 Yes 2008 73 2.52c 1.18,5.38 
Duration of wash-
out period (days)a - - 89 -9.20
b   -11.78,-6.62 
Study duration 
(weeks)a - - 96 -0.92
b   -1.33,-0.50 
Randomizationa Low risk (ref) 2007 48 -  
 Unclear 2006 57 0.80c   0.53,1.20 
Allocation 
concealmenta Low risk (ref) 2008 33 -  
 Unclear 2006 72 0.76c   0.48,1.21 
Intention-to-treat 
analysis/completersa ITT (ref) 2007 95 -  
 Completers 1981 7 0.21cc 0.11,0.39 
Risk of bias due to 
missing outcome 
dataa 
Low risk (ref) 2008 73 -  
 Unclear 2002 19 0.50c   0.32,0.81 
 High risk 2000 13 0.47 c   0.27,0.82 
Blinding  Low risk (ref) 2007 57 -  
 Unclear 2006 48 0.80c 0.52,1.23 
 High risk - - -  
Number of arms Two arms (ref) 2006 10 -  
 More than two arms 2007 95 1.11 c   0.74,1.65 
Number of 
medications Two medications (ref) 2009 33 -  
 More than two medications 2005 72 0.53
c   0.27,1.02 
Industry sponsored 
drug or not Non-sponsored drugs (ref) 2006 32 -  
 At least one sponsored drug 2007 65 1.15
c  0.73,1.81 
Percentage patients 
randomized to PBO - - 105 0.00
b -0.04,0.03 
 25 
(ref) = the reference category for dichotomous outcomes 
aCharacteristics in these columns resulted in a statistically significant association with publication year.  
bThese coefficients show the average increase or decrease for the respective moderator associated with a 
10-year increase in publication year. For example, a 10 years newer study would on average have 79.77 
more participants. 
cThese coefficients show the average odds ratio of the respective moderator associated with 10-year 
increase in publication year. For example, a 10 years newer study would on average have 2.52 times the 
odds of having a baseline severity entry minimum score.  
M1 – M5 are drug mechanisms of action according to the “Neuroscience-based Nomenclature (NbN)” 
(49): M1 = receptor antagonists (D2) clopenthixol, fluphenazine, haloperidol, perphenzaine, pimozide, 
pipotiazine, sulpiride, trifluoperazine. M2 = receptor antagonists (D2, 5-HT2) chlorpromazine, 
iloperidone,  loxapine, lurasidone, olanzapine, sertindole, thioridazine, ziprasidone, zotepine. M3 = 
receptor partial agonists (D2, 5-HT1A) aripiprazole, brexpiprazole, cariprazine. M4= receptor antagonists 
(D2, 5-HT2, NE alpha2) asenapine, paliperidone, risperidone. M5= receptor antagonist (D2, 5-HT2) and 
reuptake inhibitor (NET) quetiapine. A few old drugs have not been classified by NbN yet. 
Scalea BPRS (ref) 1990 33   
 PANSS 2009 68 -0.02c -0.00,0.07 
Drug related 
factors      
Drug mechanisma M1  (ref) 1998 18 -  
 M2 vs M1 1999 47 0.49 c  0.26,0.92c 
 M3 vs M1 2012 12 14.79 c  2.74,79.93c 
 M4 vs M1 2008 17 4.40 c  1.17,16.51c 
 M5 vs M1 2007 7 4.79c  0.65,37.17c 
Fixed/flexible dosea Fixed dose (ref) 2008 79 -  
 Flexible dose 1997 26 0.38 c 0.24,0.60 
Mean dose 
(chlorpromazine 
equivalents)a 
- - 91 -86.95b -121.18,-52.71 
Patient related 
factors      
Percentage mena - - 91 6.81b 3.81,9.82 
Operationalized 
criteria or nota Operationalized (ref) 2007 88 -  
 Not operationalized 1977 16 0.07c 0.02,0.20 
Countrya USA (ref) 2002 45 -  
 Other or mixed 2008 60 2.32c 1.37,3.93 
Placebo responsea  - - 99 2.74b 1.60,3.88 
Drug response - - 100 0.27b -0.95,1.49 
Average age - - 100 0.64b -0.08,1.37 
Duration ill (years) - - 60 0.66b -0.21,1.53 
Baseline severity 
(PANSS total score) - - 85 -0.48
b -1.57,0.62 
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Table 2: Univariable meta-regressions 
 
Explanatory variable Coeffic
ient 
95%CrI Coefficient 
corresponds to 
N, n SMD at 
the mean 
value/refe
rence 
category 
of 
moderator 
95%CrI Mean 
value/refe
rence 
category 
of 
moderator 
Heter
ogene
ity 
SD 
95%CrI % 
hetero
geneity 
explain
ed 
Study design related factors           
Publication yeara -0.08a -0.12,-0.04 10-year increase 105, 22741 0.50 0.45,0.55 2000 0.14 0.10,0.19 12.5% 
Number of total participantsa -0.04a -0.06,-0.01 100 part. more 105, 22741 0.49 0.44,0.54 225 0.15  0.11,0.20 6.3% 
Number of sitesa -0.02a -0.04,0.00 10-site increase 96, 20941 0.49 0.44,0.55 28 0.17 0.12,0.22 - 
Number of medicationsa 0.08a 0.02,0.15 1 drug more 105, 22741 0.40 0.33,0.47 2 drugs 0.15 0.11,0.20 6.3% 
Baseline severity entry minimum 
scorea 
-0.17a -0.29,-0.04 Min. entry score 102, 22291 0.61 0.50,0.72 without 
entry score 
0.15 0.11,0.20 6.3% 
Industry sponsored drug or nota -0.15a -0.25,-0.05 Sponsored 97, 22397 0.57 0.48,0.66 non-
sponsored 
0.14 0.10,0.19 12.5% 
Scale (PANNS or BPRS) a 0.18a 0.07,0.30 BPRS 101, 22589 0.43 0.38,0.48 PANSS 0.15 0.11,0.20 6.3% 
Risk of bias due to missing 
outcome data  
0.05 -0.03,0.12 Unclear or high risk 105, 22741 0.45 0.40,0.50 low risk 0.16 0.12,0.21 0% 
Percentage of academic sites 0.01 -0.01,0.03 10% increase 59, 9379 0.57 0.51,0.64 58% 0.15 0.08,0.23 6.3% 
Number of arms 0.00 -0.04,0.04 1 arm increase 105, 22741 0.47 0.38,0.57 2 arms 0.16 0.12,0.21 0% 
Minimum duration of the wash-
out phase 
0.03 -0.01,0.06 10-day increase 89, 18586 0.50 0.45,0.55 9 0.15 0.11,0.20 6.3% 
Percentage randomized to 
placebo 
0.01 -0.05,0.07 10% increase 105, 22741 0.47 0.42,0.52 28.3% 0.16 0.12,0.21 0% 
Study duration 0.10 -0.10,0.29 10-week increase 96, 22443 0.46 0.42,0.51 6.5 weeks 0.16 0.11,0.21 0% 
Blinding  0.00 -0.09,0.09 Unclear or high risk 105, 22741 0.47 0.41,0.53 low risk 0.16 0.12,0.21 0% 
Allocation concealment 0.01 -0.08,0.11 Unclear risk 105, 22741 0.46 0.39,0.53 low risk 0.16 0.12,0.21 0% 
Randomization -0.03 -0.13,0.06 Unclear risk 105, 22741 0.48 0.42,0.55 low risk 0.16 0.12,0.21 0% 
Drug related factors           
Drug mechanism M2 vs M1 -0.13 -0.28,0.01 M2 101, 22315b 0.60 0.48,0.73 M1 0.16b 0.12,0.21 0% 
Drug mechanism M3 vs M1a -0.26a -0.43,-0.09 M3 101, 22315b 0.60 0.48,0.73 M1 0.16b 0.12,0.21 0% 
Drug mechanism M4 vs M1 -0.11 -0.28,0.05 M4 101, 22315b 0.60 0.48,0.73 M1 0.16b 0.12,0.21 0% 
Drug mechanism M5 vs M1 -0.18 -0.39,0.03 M5 101, 22315b 0.60 0.48,0.73 M1 0.16b 0.12,0.21 0% 
Fixed/flexible dose 0.04 -0.08,0.17 Flexible dose 105, 22741 0.46 0.41,0.51 fixed dose 0.16b 0.12,0.21 0% 
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Mean dosea 0.03a 0.00,0.05 100 CPZ unit 
increase 
91, 19957 0.49 0.45,0.54 580.6 0.15 0.11,0.20 6.3% 
Patient related factors           
Operationalized criteria or nota 0.22a 0.04,0.40 No operationalized 
criteria 
103, 22151 0.45 0.41,0.50 Op.criteria 0.16 0.11,0.20 0% 
Placebo response (mean PANSS 
change score in placebo arm) a 
-0.15a -0.21,-0.09 10-unit PANSS  
increase 
99, 22520 0.48 0.44,0.52 6.24 0.13 0.08,0.18 18.8% 
Drug response (mean change 
score in drug arm) 
0.05 -0.02,0.12 10-unit PANSS 
increase 
100, 22564 0.46 0.42,0.51 17.45 0.16 0.11,0.21 0% 
Average age -0.08 -0.20,0.03 10-year increase 100, 22567 0.47 0.42,0.51 38 0.16 0.11,0.20 0% 
Baseline severity 0.10 -0.01,0.20 10-unit PANSS 
increase 
85, 21259 0.45 0.41,0.50 94.6 0.16 0.11,0.21 0% 
Duration ill -0.07 -0.23,0.08 10-year increase 60, 14278 0.47 0.42,0.53 14 0.15 0.09,0.21 6.3% 
Percentage of men -0.01 -0.04,0.02 10% increase 91, 21119 0.46 0.41,0.51 66.3% 0.16 0.12,0.21 0% 
Country 0.02 -0.07,0.12 Non-USA or mixed 
study 
105, 22741 0.45 0.38,0.53 USA 0.16 0.12,0.21 0% 
First episode#           
Duration of current episode#           
In-outpatients at study start#           
aStatistically significant moderators, N = number of studies, n= number of patients.  
“Coefficient corresponds to”: for example publication year: a 10-year increase in publication year on the average reduces the standardized mean difference by 0.08 
units.  
Standardized mean difference at the mean value/reference category = standardised mean difference after adjustment for covariate. For example, after adjustment for 
publication year, a study published in 2000 would on average have an standardized mean difference of 0.50, or non-sponsored studies would have an average 
standardized mean difference of 0.57. M1 – M5 are drug mechanisms of action according to the “Neuroscience-based Nomenclature” (49): M1 = receptor antagonists 
(D2) clopenthixol, fluphenazine, haloperidol, perphenzaine, pimozide, pipotiazine, sulpiride, trifluoperazine. M2 = receptor antagonists (D2, 5-HT2) chlorpromazine, 
iloperidone,  loxapine, lurasidone, olanzapine, sertindole, thioridazine, ziprasidone, zotepine. M3 = receptor partial agonists (D2, 5-HT1A) aripiprazole, 
brexpiprazole, cariprazine. M4= receptor antagonists (D2, 5-HT2, NE alpha2) asenapine, paliperidone, risperidone. M5= receptor antagonist (D2, 5-HT2) and 
reuptake inhibitor (NET) quetiapine. A few old drugs have not been classified by NbN yet. bNumbers for the overall model 
#Not enough data were available for the variable number of patients with a first episode and there were too few data for ‘duration of the current episode’. The vast 
majority of studies included only inpatients. Therefore these parameters could not be analyzed in a meaningful way. 
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Table 3: Multivariable meta-regression model 
 
Moderator Coefficient  95% CrI 
Coefficient 
corresponds 
to 
Interpretation Proba-bility b   
Placebo 
responsea -0.13 
-0.20,-
0.06a 
10-unit 
increase 
A 10 PANSS points higher mean 
change score in the placebo arm 
would reduce the standardized mean 
difference on average by 0.13 units 
80.6% 
Industry 
sponsored 
or nota 
-0.16 -0.28,-0.04a 
Industry 
sponsored 
The standardized mean difference for 
studies including at least one 
sponsored drug would be on average 
0.16 units smaller than non-sponsored 
studies 
82.8% 
Publication 
year -0.02 
-
0.09,0.05 
10-year 
increase 
A 10 years later published study 
would have an on average 0.02 units 
smaller standardized mean difference 
25.0% 
Sample 
size 0.01 
-
0.02,0.04 
100 
participants 
increase 
A 100 participants larger study would 
have an on average 0.01 units larger 
standardized mean difference 
3.3% 
Mean dose 0.01 -0.03,0.04 
100 
chlorpromazine 
units increase 
A 100 chlorpromazine units higher 
mean dose would increase the 
standardized mean difference on 
average by 0.01 units 
3.3% 
Baseline 
severity 
minimum 
score 
0.05 -0.13,0.21 
Baseline 
severity 
minimum score 
The standardized mean difference for 
studies having a minimum baseline 
severity entry score would be on 
average 0.05 units larger than studies 
without a minimum baseline severity 
entry score. 
48.4% 
 
Summary of the model: 78 studies with 19060 participants, heterogeneity standard deviation 0.11 
(0.07,0.16), the model explained 31.3% of the heterogeneity 
 
aStatistically significant moderators. b In a simulation process, this is the probability that a model that 
includes this moderator would have been selected as the preferred model 
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Legends of Figures 
 
Figure 1: Number of patients at least minimally improved and at least much improved 
PANSS = Positive and Negative Syndrome Scale, BPRS = Brief Psychiatric Rating Scale, CGI = Clinical 
Global Impression Improvement Scale, CrI = Credible Interval 
 
Figure 2: Quality of life and social functioning 
*Some studies compared two antipsychotics with placebo. #SMDs were obtained from a random effects 
model assuming a common heterogeneity across all drugs, SMD = standardized mean difference, SD = 
standard deviation, CrI = credible interval 
 
Figure 3: Single antipsychotics compared to placebo: positive and negative symptoms (Figure 3 is a panel 
of figures) 
Footnote: It should be noted that these are raw effect sizes that have not been corrected for the effects of 
increasing placebo response over the years. The effect sizes of the single drugs have not been compared 
with each other. Moreover, for some drugs few data were available making the results unreliable. For 
example, the results of positive symptoms for chlorpromazine are based on only one study with 54 
patients. This caused uncertainty about the true effect which is expressed by a large 95% credible interval.    
Abbreviations: N = number of trials, n = number of participants, SMD = standardized mean difference, 
SD = standard deviation, CrI = credible interval, ARI = aripiprazole, ASE = asenapine, BLO = 
blonanserine, BRE = brexpiprazole, CAR = cariprazine, CPZ = chlorpromazine, FLUPE = flupenthixol, 
FLUPH = fluphenazine, HAL = haloperidol, ILO = iloperidone, LOX = loxapine, LUR = lurasidone, 
MOL = molindone, OLA = olanzapine, PAL = paliperidone, QUE = quetiapine, RIS = risperidone, SER = 
sertindole, THIOT = thiothixene, ZIP = ziprasidone, ZOT = zotepine 
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Figure 4: Single antipsychotics compared to placebo: weight gain, QTc prolongation, prolactin increase, 
antiparkinson medication (Figure 4 is a panel of figures) 
It should be noted that for some drugs few data were available making the results unreliable. For example, 
the results on weight gain for reserpine are based on only one study with 20 patients. This caused 
uncertainty about the true effect which is expressed by a large 95% credible interval. The effect sizes of 
the single drugs have not been compared with each other, but 95% CrIs that do not overlap with the y-axis 
mean statistically significant differences compared to placebo. Abbreviations: N = number of trials, n = 
number of participants, r = number of participants with an event, RR = relative risk, SMD = standardized 
mean difference, SD = standard deviation, CrI = credible interval, ARI = aripiprazole, ASE = asenapine, 
BRE = brexpiprazole, BUTA = butaperazine, CAR = cariprazine, CLOP = clopenthixol, CPZ = 
chlorpromazine, FLUPH = fluphenazine, HAL = haloperidol, ILO = iloperidone, LOX = loxapine, LUR = 
lurasidone, MEL = melperone, OLA = olanzapine, PAL = paliperidone, QUE = quetiapine, RES = 
reserpine, RIS = risperidone, SER = sertindole, THIOT = thiothixene, THIOR = thioridazine, TRIFLU = 
trifluperazine, ZIP = ziprasidone, ZOT = zotepine 
* These relative risks were obtained after a continuity correction and from a fixed effect model. 
 
Figure 5: Effect sizes over time (Figure 5 is a panel of figures) 
Figure 5a: Efficacy of antipsychotic drugs compared to placebo versus publication year 
Figure 5b: Efficacy of haloperidol compared to placebo versus publication year  
Figure 5c: Placebo response (PANSS total score change from baseline) versus publication year  
Figure 5d: Drug response (PANSS total score change from baseline) versus publication year  
Footnote: SMD = standardized mean difference, PANSS = Positive and Negative Syndrome Scale, B = 
regression coefficient 
 
Figure 6: Contour enhanced funnel-plot 
Footnote: se = standard error, SMD = standardized mean difference, p = p-value  
